XRAY — DENTSPLY SIRONA Inc.

Is XRAY overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Instruments & Supplies

Strong Oversold As of November 17, 2026

DENTSPLY SIRONA Inc. (XRAY) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $8.60. The rating moved from Oversold to Strong Oversold on November 14, 2026.

See all oversold Healthcare stocks →

AI analysis

DENTSPLY SIRONA Inc. (XRAY) is positioned as a leader in dental equipment and consumables with a sizeable installed base that provides recurring revenue and cross-sell opportunities. Near-term performance is likely to hinge on procedure volumes, capital spending by dental practices, and execution of cost and product initiatives; absent clear sector catalysts, price action is expected to be range-bound with downside risk if execution or demand deteriorates. Monitoring upcoming quarterly results, cash-flow trends, and any operational updates will be key to assessing whether current stabilization efforts translate into sustainable margin recovery.

Key factors

  • Established market position in dental equipment, consumables and imaging with a recurring revenue base from consumables and service contracts
  • Recent revenue and margin pressure historically from product refresh cycles and slower procedure volumes, leaving near-term growth constrained
  • Installed base provides cross-sell and recurring service opportunity that can stabilize cash flow even with cyclical top-line
  • Operational cost controls and restructuring initiatives could improve margins if execution continues
  • Limited short-term macro/sector catalysts in the provided market commentary; defensive flows into larger healthcare names may leave XRAY overlooked
  • Valuation and current price reflect investor concerns, offering some downside protection if near-term results stabilize

Risks

  • Sustained weakness in dental procedure volumes or delayed dentist capital spending that reduces equipment replacement and upgrade cycles
  • Competitive pressure from other dental OEMs and cheaper imports that compress pricing and margins
  • Execution risk on product rollouts, integration of prior acquisitions, and delivery of expected cost savings
  • Supply chain disruptions or component shortages that delay shipments and revenue recognition
  • Foreign currency exposure and international demand variability given global footprint
  • Balance sheet and liquidity risk if cash flow weakens and debt obligations remain elevated
  • Regulatory, warranty or litigation exposures that could generate unexpected charges or reputational impacts

See today's live rating, score and targets

Members see the live hourly rating for XRAY — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.